QB3 Seminar: Tito Serafini, Atreca. "Lessons Learned at Atreca from Founding Through IPO"

Redwood City-based Atreca ("BCEL" on Nasdaq) is developing novel therapeutics based on a deep understanding of the human immune response. In June, Atreca's IPO raised $125 million. Tito Serafini led Atreca as CEO from inception through 2018. Join us on October 31 to get Tito's insights and reflections on the company's founding and growth.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Noon to 1:00 PM, Thursday, October 31, 2019

This is a brown bag event.

About the Speaker


Dr. Serafini is one of the three principal founders of Atreca and was CEO from the Company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, Dr. Serafini is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.

Dr. Serafini received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University (advised by Dr. James Rothman), and he performed postdoctoral research at the University of California, San Francisco in the laboratory of Dr. Marc Tessier-Lavigne.